The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis

Lupus ◽  
2011 ◽  
Vol 20 (13) ◽  
pp. 1442-1449 ◽  
Author(s):  
HS Koo ◽  
YC Kim ◽  
SW Lee ◽  
DK Kim ◽  
K-H Oh ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Rank Test ◽  
Systemic Steroid ◽  
Diagnostic Code ◽  
Composite Outcome ◽  
The Mean ◽  
Stage Renal Disease ◽  
End Stage

Debate continues about the optimal treatment modality of lupus nephritis (LN). We compared the efficacy and safety of intravenous cyclophosphamide (CYC) and mycophenolate mofetil (MMF) for LN treatment in Korea. After searching for systemic lupus erythematosus (SLE) patients diagnosed between 1998 and 2007 with the diagnostic code of ICD10, we selected the 71 patients who were treated with CYC or MMF without any other immunosuppressant except systemic steroid. Composite outcome was defined as progression to end-stage renal disease (ESRD) and/or all-cause mortality. The initial manifestations of the CYC group were more severe than those of the MMF group. The mean daily MMF dose was 980 ± 100 mg for 21.67 ± 18.25 months. The mean monthly dose per CYC pulse therapy was 850 ± 30 mg for 17.04 ± 13.15 months. The incidence of composite outcome was 5/20 (25%) in the MMF group and 4/51 (7.8%) in the CYC group. The relative risk (RR) for composite outcome in the CYC group was 0.249 (95% CI for RR: 0.067–0.934, p = 0.039) compared with the MMF group with Cox's hazard proportional analysis. In Kaplan–Meier analysis, the probability of composite outcome was lower in the CYC group than in the MMF group (Log rank test p-value = 0.026). The results of this retrospective study suggest that intravenous CYC therapy may be more efficacious in averting ESRD and death than MMF. These results need to be confirmed in a larger randomized controlled trial.

scholarly journals Correlation between Calcium Phosphorus Product and Mean Arterial Pressure among Hemodialysis Patients with End Stage Renal Disease

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Muhammad Nadeem ◽  
Mansoor Abbas Qaisar ◽  
Ali Hassan Al Hakami ◽  
Fateh Sher Chattah ◽  
Muhammad Muzammil ◽  
...  
Keyword(s):  
Mean Arterial Pressure ◽  
Arterial Pressure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Age Group ◽  
Calcium Phosphorus ◽  
The Mean ◽  
Stage Renal Disease ◽  
End Stage

Background: The mean arterial pressure serves as an expression of blood pressure in patients on chronic hemodialysis. Serum calcium phosphorus product is considered as a risk factor of vascular calcification that is associated with hypertension in the patients of end stage renal disease. The literature regarding this relationship is inconsistent therefore this study is designed to determine the correlation between calcium phosphorus product and mean arterial pressure among hemodialysis patients with end stage renal disease. Methods: A total of 110 patients of end stage renal disease on hemodialysis for at least one year, 20 to 60 years of age were included. Patients with primary or tertiary hyperparathyroidism, peripheral vascular disease, malignancy, hypertension secondary to any cause other than kidney disease were excluded. Mean arterial pressure was calculated according to the standard protocol in lying position. Blood samples for estimation of serum calcium and phosphorous were taken and was sent immediately to the laboratory for serum analysis. Results: Mean age was 44.17 ± 10.94 years. Mean calcium phosphorous product was 46.71 ± 7.36 mg/dl and mean arterial pressure was 103.61 ± 12.77 mmHg. The values of Pearson correlation co-efficient (r) were 0.863 for age group 20 to 40 years and 0.589 for age group 41 to 60 years. This strong positive correlation means that high calcium phosphorous product goes with high mean arterial pressure (and vice versa) for both the age groups. Conclusion: A strong positive relationship exists between the mean arterial pressure and calcium phosphorous product and is independent of patients’ age.

scholarly journals Lupus Nephritis in Males: Clinical Features, Course, and Prognostic Factors for End-Stage Renal Disease

2017 ◽  
Vol 2 (5) ◽  
pp. 905-912 ◽  
Author(s):  
Andrés Urrestarazú ◽  
Gabriela Otatti ◽  
Ricardo Silvariño ◽  
Mariela Garau ◽  
Ruben Coitiño ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Lupus Nephritis ◽  
Renal Disease ◽  
Clinical Features ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals End-stage renal disease due to lupus nephritis among children in the US, 1995-2006

2011 ◽  
Vol 63 (7) ◽  
pp. 1988-1997 ◽  
Author(s):  
Linda T. Hiraki ◽  
Bing Lu ◽  
Steven R. Alexander ◽  
Tamara Shaykevich ◽  
Graciela S. Alarcón ◽  
...  
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
The Us ◽  
Stage Renal Disease ◽  
End Stage

Predictors of mortality and end stage renal disease in Saudi patients with lupus nephritis

Lupus ◽  
2011 ◽  
Vol 20 (12) ◽  
pp. 1329-1335 ◽  
Author(s):  
H Al Durahim ◽  
G Al Ghamdi ◽  
A Al Seraya ◽  
R Alkhiari ◽  
A Al Sayyari
Keyword(s):  
Lupus Nephritis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Predictors Of Mortality ◽  
Stage Renal Disease ◽  
End Stage ◽  
Saudi Patients
Sign in / Sign up

Export Citation Format

Share Document